First Wave BioPharma Announces Streamlining of Clinical
First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical...
Source: globenewswire.com
Page 14 - First Wave News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from First Wave. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In First Wave Today - Breaking & Trending Today
Why Is First Wave Biopharma (FWBI) Stock Up 148% Today?
Heading into today, FWBI had slumped 23% in the previous three months and 97% in 2023 First Wave Biopharma (NASDAQ: ) stock is soaring over 140% today. This…
Source: biztoc.com
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and AdrulipaseBOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced
Source: yahoo.com
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
BOCA RATON, Fla., Dec. 27, 2023 -- First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal ...
Source: marketscreener.com
First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company
Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal disease clinical pipeline A concurrent institutional...
Source: marketscreener.com